Implementing a Therapy for Complex Trauma in French-Speaking Settings

NCT ID: NCT07123974

Last Updated: 2025-08-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-01-22

Study Completion Date

2025-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Many individuals living with borderline personality disorder (BPD) have experienced childhood trauma, such as abuse or neglect. A significant number of them also meet the criteria for post-traumatic stress disorder (PTSD). However, standard psychotherapies often do not address both conditions at the same time, which can affect treatment outcomes.

A research team in Germany developed and validated a 45-week individual psychotherapy that has shown promising results for individuals coping with both BPD and PTSD. It has already been adapted and offered in English-speaking settings such as Toronto and Boston.

This study aims to adapt this therapy into French in Quebec. Over 24 months, we will conduct a mixed-methods observational study to evaluate changes in symptoms (BPD, PTSD, and other comorbidities) and in daily functioning.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Borderline Personality Disorder (BPD) Complex Post-Traumatic Stress Disorder (CPTSD) Post-Traumatic Stress Disorder, PTSD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dialectical Behaviour Therapy for Post-Traumatic Stress Disorder (DBT-PTSD)

Participants receive the Dialectical Behaviour Therapy for Post-Traumatic Stress Disorder (DBT-PTSD) psychotherapy over 45 weekly individual outpatient sessions. All participants followed the same treatment protocol.

Group Type EXPERIMENTAL

Dialectical Behaviour Therapy for Post-Traumatic Stress Disorder (DBT-PTSD)

Intervention Type BEHAVIORAL

DBT-PTSD is 45-week individual psychotherapy (DBT-PTSD) designed to treat adults presenting with both borderline personality disorder (BPD) and complex post-traumatic stress disorder (C-PTSD). The intervention integrates dialectical behavior therapy (DBT) skills, trauma-focused exposure-based interventions, and strategies from compassion-focused therapy and acceptance and commitment therapy. All participants will receive the full sequence of the therapy in outpatient settings, following the structured treatment protocol.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dialectical Behaviour Therapy for Post-Traumatic Stress Disorder (DBT-PTSD)

DBT-PTSD is 45-week individual psychotherapy (DBT-PTSD) designed to treat adults presenting with both borderline personality disorder (BPD) and complex post-traumatic stress disorder (C-PTSD). The intervention integrates dialectical behavior therapy (DBT) skills, trauma-focused exposure-based interventions, and strategies from compassion-focused therapy and acceptance and commitment therapy. All participants will receive the full sequence of the therapy in outpatient settings, following the structured treatment protocol.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* PTSD according to the DSM caused by sexual or physical abuse up to the age of 18.
* Three or more criteria for borderline personality disorder (BPD) according to the SCID-II, including affective instability.
* Availability for one year of outpatient treatment (psychotherapy).
* Access to an email address usable for secure links to questionnaires.
* Fluent French-speaking.

Exclusion Criteria

* Psychotic disorder, bipolar I disorder, intellectual disability, or severe psychopathology requiring immediate care as determined by the treating psychiatrist.
* Severe suicide attempt within two months prior to the inclusion visit.
* Medical condition preventing inclusion (e.g., pregnancy).
* Highly unstable living situation (e.g., homelessness).
* Current substance dependence.
* Having received specific treatment for PTSD or BPD within the year preceding the inclusion visit.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ciusss de L'Est de l'Île de Montréal

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Lionel Cailhol

Role: PRINCIPAL_INVESTIGATOR

Ciusss de l'Est de Montréal, Université de Montréal

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Institut universitaire en santé mentale de Montréal

Montreal, Quebec, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2023-3031

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.